/

Società

Eg

Non verificato

Egle Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati

02/12/2025

Salute

Scienza

Medicina - Varie

Farmaceutica

Biotecnologia

Egle Therapeutics Initiates Phase 1 Healthy Volunteer Study of EGL-003, a Next Generation Treg IL-2 Agonist for Atopic Dermatitis

Fonte

Egle Therapeutics

Emittente

1.00

0

22/04/2025

Fiere

Industria

Oncologia

Salute

Biotecnologia

Sanità

Medicina - Varie

Farmaceutica

Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting

Fonte

Egle Therapeutics

Emittente

1.00

0

17/03/2025

Biotecnologia

Sanità

Salute

Farmaceutica

Oncologia

Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030

Fonte

Egle Therapeutics

Emittente

1.00

0

13/01/2025

Mercato del lavoro

Oncologia

Salute

Medicina - Varie

Scienza

Farmaceutica

Biotecnologia

Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer

Fonte

Egle Therapeutics

Emittente

1.00

0

25/10/2024

Eventi

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting

Fonte

Egle Therapeutics

Emittente

1.00

0

12/09/2024

Mercato del lavoro

Biotecnologia

Sanità

Salute

Oncologia

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

Fonte

Egle Therapeutics

Emittente

1.00

0

Seguaci

0

Compatibilità

0